Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00101998




Registration number
NCT00101998
Ethics application status
Date submitted
18/01/2005
Date registered
19/01/2005
Date last updated
30/08/2017

Titles & IDs
Public title
Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects
Secondary ID [1] 0 0
767905/008
Secondary ID [2] 0 0
3753-009
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Constipation 0 0
Bowel Dysfunction 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: Alvimopan 0.5 mg Twice Daily (BID) - 0.5 milligrams (mg) of alvimopan was administered orally BID for 3 weeks.

Experimental: Alvimopan 1 mg Once Daily (QD) - 0.5 mg of alvimopan was administered orally QD for 3 days, then 1 mg of alvimopan QD for the remaining 3 weeks. Placebo was administered orally QD to maintain the blind.

A protocol amendment dropped this arm because another study had demonstrated 1 mg QD treatment to have similar efficacy but a less favorable gastrointestinal-related safety profile compared with 0.5 mg BID treatment.

Experimental: Alvimopan 1 mg Twice Daily (BID) - 0.5 mg of alvimopan was administered orally BID for 3 days, then 1 mg of alvimopan BID for the remaining 3 weeks.

Placebo comparator: Placebo - Placebo was administered orally BID for 3 weeks.
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in weekly SCBM frequency. A SCBM is a spontaneous and complete bowel movement, which means a bowel movement that occurs with no laxative use in the prior 24 hours and leaves the subject with the feeling of complete evacuation of the rectum.
Timepoint [1] 0 0
Secondary outcome [1] 0 0
Additional measures of Bowel movement (BM) frequency and symptoms, safety profile of the treatment regimens and any changes in pain intensity or opioid use.
Timepoint [1] 0 0

Eligibility
Key inclusion criteria
Inclusion criteria:

* Participant is in any stage of cancer but has a minimum life expectancy of at least 3 months at the time of the Screening Visit.
* Participant is taking opioid therapy for persistent cancer pain.
* Participant meets the definition of opioid-induced bowel dysfunction as follows: Since starting opioid therapy, the subject has had decreased bowel movement (BM) frequency and at least one of the following constipation symptoms [sensation of incomplete evacuation, difficulty in expelling stool (straining), hard stools (abnormal stool consistency)].
* Participant understands the procedures, agrees to participate in the study, and has signed and dated the informed consent form prior to the initiation of any study-related activities, including discontinuation of pre-study laxative regimen or other prohibited medications.
* Participant is able and willing to comply with a daily paper diary and is capable of completing paper questionnaires at study visits.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

* Participant is pregnant or lactating, or planning to become pregnant.
* Participant is not ambulatory.
* Participant has participated in another trial with an investigational drug (unapproved), device or procedure within 30 days of the Screening Visit.
* Participant is unable to eat, drink, take/hold down oral medications.
* Participant is taking opioids for the management of drug addiction.
* Participant is unable or unwilling to discontinue the use of and/or refrain from using laxatives of all types and formulation at the Screening Visit and throughout the entire study.
* Participant has severe constipation that has not been appropriately managed such that the subject is at immediate risk of developing serious complications of constipation. This would include a subject who has reported no bowel movement for 7 consecutive days prior to the Screening Visit.
* Participant with gastrointestinal or pelvic disorders known to affect bowel transit, produce gastrointestinal (GI) obstruction, or contribute to bowel dysfunction.
* Participant is currently taking vinca alkyloids or plans to take vinca alkyloids during the study.
* Participant is currently undergoing abdominal radiation therapy and/or plans to undergo abdominal radiation therapy during the study.
* Participant is human immunodeficiency virus (HIV)-infected, has active hepatitis (any subtype including ongoing chronic hepatitis B), or has ever been infected with hepatitis C.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2003
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/05/2006
Sample size
Target
Accrual to date
Final
233
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
GSK Investigational Site - St Leonards
Recruitment hospital [2] 0 0
GSK Investigational Site - Redcliffe
Recruitment hospital [3] 0 0
GSK Investigational Site - South Brisbane
Recruitment hospital [4] 0 0
GSK Investigational Site - Daw Park
Recruitment hospital [5] 0 0
GSK Investigational Site - Malvern
Recruitment postcode(s) [1] 0 0
2065 - St Leonards
Recruitment postcode(s) [2] 0 0
4020 - Redcliffe
Recruitment postcode(s) [3] 0 0
4101 - South Brisbane
Recruitment postcode(s) [4] 0 0
5041 - Daw Park
Recruitment postcode(s) [5] 0 0
3144 - Malvern
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
Nevada
Country [17] 0 0
United States of America
State/province [17] 0 0
New Mexico
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
North Dakota
Country [21] 0 0
United States of America
State/province [21] 0 0
Ohio
Country [22] 0 0
United States of America
State/province [22] 0 0
Oregon
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Virginia
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
United States of America
State/province [27] 0 0
Wisconsin
Country [28] 0 0
Argentina
State/province [28] 0 0
Buenos Aires
Country [29] 0 0
Argentina
State/province [29] 0 0
Santa Fe
Country [30] 0 0
Canada
State/province [30] 0 0
Manitoba
Country [31] 0 0
Canada
State/province [31] 0 0
Newfoundland and Labrador
Country [32] 0 0
Canada
State/province [32] 0 0
Ontario
Country [33] 0 0
Canada
State/province [33] 0 0
Quebec
Country [34] 0 0
Czechia
State/province [34] 0 0
Brno
Country [35] 0 0
Czechia
State/province [35] 0 0
Plzen
Country [36] 0 0
Czechia
State/province [36] 0 0
Praha 10
Country [37] 0 0
Finland
State/province [37] 0 0
Helsinki
Country [38] 0 0
France
State/province [38] 0 0
Bordeaux Cedex
Country [39] 0 0
France
State/province [39] 0 0
Vandoeuvre-Les-Nancy
Country [40] 0 0
France
State/province [40] 0 0
Villejuif Cedex
Country [41] 0 0
Germany
State/province [41] 0 0
Niedersachsen
Country [42] 0 0
Hong Kong
State/province [42] 0 0
Kwun Tong
Country [43] 0 0
Hong Kong
State/province [43] 0 0
Pokfulam
Country [44] 0 0
Hong Kong
State/province [44] 0 0
Shatin
Country [45] 0 0
Hungary
State/province [45] 0 0
Budapest
Country [46] 0 0
Hungary
State/province [46] 0 0
Miskolc
Country [47] 0 0
Hungary
State/province [47] 0 0
Zalaegerszeg-Pozva
Country [48] 0 0
India
State/province [48] 0 0
Bangalore
Country [49] 0 0
Italy
State/province [49] 0 0
Campania
Country [50] 0 0
Italy
State/province [50] 0 0
Emilia-Romagna
Country [51] 0 0
Italy
State/province [51] 0 0
Liguria
Country [52] 0 0
Italy
State/province [52] 0 0
Lombardia
Country [53] 0 0
Italy
State/province [53] 0 0
Piemonte
Country [54] 0 0
Italy
State/province [54] 0 0
Sicilia
Country [55] 0 0
Italy
State/province [55] 0 0
Toscana
Country [56] 0 0
Korea, Republic of
State/province [56] 0 0
Seoul
Country [57] 0 0
Netherlands
State/province [57] 0 0
Leeuwarden
Country [58] 0 0
New Zealand
State/province [58] 0 0
Dunedin
Country [59] 0 0
New Zealand
State/province [59] 0 0
Hastings
Country [60] 0 0
New Zealand
State/province [60] 0 0
Wellington
Country [61] 0 0
Pakistan
State/province [61] 0 0
Lahore
Country [62] 0 0
Peru
State/province [62] 0 0
Lima
Country [63] 0 0
Philippines
State/province [63] 0 0
Manila
Country [64] 0 0
Poland
State/province [64] 0 0
Bialystok
Country [65] 0 0
Poland
State/province [65] 0 0
Olsztyn
Country [66] 0 0
Poland
State/province [66] 0 0
Otwock
Country [67] 0 0
Poland
State/province [67] 0 0
Poznan
Country [68] 0 0
Portugal
State/province [68] 0 0
Lisboa
Country [69] 0 0
Russian Federation
State/province [69] 0 0
Moscow
Country [70] 0 0
Russian Federation
State/province [70] 0 0
St'Petersburg
Country [71] 0 0
South Africa
State/province [71] 0 0
KwaZulu- Natal
Country [72] 0 0
South Africa
State/province [72] 0 0
Groenkloof, Pretoria
Country [73] 0 0
South Africa
State/province [73] 0 0
Houghton, Johannesburg
Country [74] 0 0
South Africa
State/province [74] 0 0
Kenilworth, Cape Town
Country [75] 0 0
Spain
State/province [75] 0 0
Alcorcon
Country [76] 0 0
Spain
State/province [76] 0 0
Barcelona
Country [77] 0 0
Spain
State/province [77] 0 0
Cordoba
Country [78] 0 0
Spain
State/province [78] 0 0
Granada
Country [79] 0 0
Spain
State/province [79] 0 0
Jaén
Country [80] 0 0
Spain
State/province [80] 0 0
Madrid
Country [81] 0 0
Spain
State/province [81] 0 0
Sabadell / Barcelona
Country [82] 0 0
Spain
State/province [82] 0 0
Serra / Valencia
Country [83] 0 0
Spain
State/province [83] 0 0
Sevilla
Country [84] 0 0
Spain
State/province [84] 0 0
Soria
Country [85] 0 0
Spain
State/province [85] 0 0
Valencia
Country [86] 0 0
Taiwan
State/province [86] 0 0
Taipei
Country [87] 0 0
Thailand
State/province [87] 0 0
Chiang Mai
Country [88] 0 0
United Kingdom
State/province [88] 0 0
London
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Newcastle-upon-Tyne
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Nottingham
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Sheffield
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Surrey

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
GlaxoSmithKline
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials, MD
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT00101998